Literature DB >> 19685112

Functional analysis of ryanodine receptor type 1 p.R2508C mutation in exon 47.

Takako Migita1, Keiko Mukaida, Hiroshi Hamada, Toshimichi Yasuda, Toshiaki Haraki, Ichizo Nishino, Nobuyuki Murakami, Masashi Kawamoto.   

Abstract

PURPOSE: Malignant hyperthermia (MH) is a pharmacogenetic disorder of intracellular calcium homeostasis with an autosomal dominant inheritance. Most of the reported mutations in exon 47 were identified in Asian patients. However, no functional analysis of p.R2508C has been performed. We therefore conducted a functional analysis of the mutation by altering calcium homeostasis in human embryonic kidney (HEK) 293 cells transfected with the p.R2508C mutation in exon 47 of the ryanodine receptor 1 (RYR1).
METHODS: The entire RYR1 coding region from genomic DNA, which was extracted from the biopsied muscle specimens of two patients, was sequenced. The p.R2508C mutation was introduced into rabbit RYR1 cDNA, and wild-type or p.R2508C mutant cDNAs were transfected into HEK-293 cells. Using the calcium-sensitive probe Fura 2, we utilized the 340/380 nm ratio to analyze alterations in calcium homeostasis following treatment with caffeine and 4-chloro-m-cresol (4CmC).
RESULTS: Genetic analysis revealed a C-->T point mutation of RYR1 exon 47 at position 7522, resulting in an amino acid exchange of arginine for cysteine at amino acid 2508. The half-maximal activation concentrations (EC(50)) of caffeine and 4CmC for HEK-293 cells transfected with the p.R2508C mutation were 1.86 +/- 0.23 mM and 73.14 +/- 19.44 microM, while those for wild-type RYR1 were 2.62 +/- 0.23 mM and 179.31 +/- 35.23 microM, respectively.
CONCLUSION: We demonstrated that the transfected RYR1 mutant was more sensitive to caffeine and 4CmC than wildtype RYR1. These findings suggest that the p.R2508C mutation may be pathogenetic for susceptibility to MH.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19685112     DOI: 10.1007/s00540-009-0746-3

Source DB:  PubMed          Journal:  J Anesth        ISSN: 0913-8668            Impact factor:   2.078


  17 in total

1.  Guidelines for molecular genetic detection of susceptibility to malignant hyperthermia.

Authors:  A Urwyler; T Deufel; T McCarthy; S West
Journal:  Br J Anaesth       Date:  2001-02       Impact factor: 9.166

2.  Central core disease is due to RYR1 mutations in more than 90% of patients.

Authors:  Shiwen Wu; M Carlos A Ibarra; May Christine V Malicdan; Kumiko Murayama; Yasuko Ichihara; Hirosato Kikuchi; Ikuya Nonaka; Satoru Noguchi; Yukiko K Hayashi; Ichizo Nishino
Journal:  Brain       Date:  2006-04-18       Impact factor: 13.501

3.  Fulminant-type malignant hyperthermia in Japan: cumulative analysis of 383 cases.

Authors:  Takako Migita; Keiko Mukaida; Masashi Kawamoto; Masako Kobayashi; Osafumi Yuge
Journal:  J Anesth       Date:  2007-05-30       Impact factor: 2.078

Review 4.  Malignant hyperthermia: a pharmacogenetic disorder.

Authors:  Kathryn M Stowell
Journal:  Pharmacogenomics       Date:  2008-11       Impact factor: 2.533

5.  Malignant hyperthermia in Japan: mutation screening of the entire ryanodine receptor type 1 gene coding region by direct sequencing.

Authors:  Carlos A Ibarra M; Shiwen Wu; Kumiko Murayama; Narihiro Minami; Yasuko Ichihara; Hirosato Kikuchi; Satoru Noguchi; Yukiko K Hayashi; Ryoichi Ochiai; Ichizo Nishino
Journal:  Anesthesiology       Date:  2006-06       Impact factor: 7.892

Review 6.  Mutations in RYR1 in malignant hyperthermia and central core disease.

Authors:  Rachel Robinson; Danielle Carpenter; Marie-Anne Shaw; Jane Halsall; Philip Hopkins
Journal:  Hum Mutat       Date:  2006-10       Impact factor: 4.878

7.  Correlations between genotype and pharmacological, histological, functional, and clinical phenotypes in malignant hyperthermia susceptibility.

Authors:  Nicole Monnier; Geneviève Kozak-Ribbens; Renée Krivosic-Horber; Yves Nivoche; Dong Qi; Natasha Kraev; Julian Loke; Parveen Sharma; Vincenzo Tegazzin; Dominique Figarella-Branger; Norma Roméro; Paulette Mezin; David Bendahan; Jean-François Payen; Thierry Depret; David H Maclennan; Joël Lunardi
Journal:  Hum Mutat       Date:  2005-11       Impact factor: 4.878

8.  Caffeine and halothane sensitivity of intracellular Ca2+ release is altered by 15 calcium release channel (ryanodine receptor) mutations associated with malignant hyperthermia and/or central core disease.

Authors:  J Tong; H Oyamada; N Demaurex; S Grinstein; T V McCarthy; D H MacLennan
Journal:  J Biol Chem       Date:  1997-10-17       Impact factor: 5.157

9.  The Ile2453Thr mutation in the ryanodine receptor gene 1 is associated with facilitated calcium release from sarcoplasmic reticulum by 4-chloro-m-cresol in human myotubes.

Authors:  Markus Wehner; Henrik Rueffert; Fritjoff Koenig; Claus Dieter Meinecke; Derk Olthoff
Journal:  Cell Calcium       Date:  2003-08       Impact factor: 6.817

10.  Novel ryanodine receptor mutation that may cause malignant hyperthermia.

Authors:  Alexius Kaufmann; Birgit Kraft; Andrea Michalek-Sauberer; Lukas G Weigl
Journal:  Anesthesiology       Date:  2008-09       Impact factor: 7.892

View more
  2 in total

1.  Genetic and functional analysis of the RYR1 mutation p.Thr84Met revealed a susceptibility to malignant hyperthermia.

Authors:  Takashi Kondo; Toshimichi Yasuda; Keiko Mukaida; Sachiko Otsuki; Rieko Kanzaki; Hirotsugu Miyoshi; Hiroshi Hamada; Ichizo Nishino; Masashi Kawamoto
Journal:  J Anesth       Date:  2018-01-17       Impact factor: 2.078

Review 2.  Preclinical model systems of ryanodine receptor 1-related myopathies and malignant hyperthermia: a comprehensive scoping review of works published 1990-2019.

Authors:  Tokunbor A Lawal; Emily S Wires; Nancy L Terry; James J Dowling; Joshua J Todd
Journal:  Orphanet J Rare Dis       Date:  2020-05-07       Impact factor: 4.123

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.